TY - JOUR
T1 - Meticillin-resistant Staphylococcus aureus
AU - Boyce, John M.
AU - Cookson, Barry
AU - Christiansen, Keryn
AU - Hori, Satoshi
AU - Vuopio-Varkila, Jaana
AU - Kocagöz, Sesin
AU - Öztop, A. Yasemin
AU - Vandenbroucke-Grauls, Christina M.J.E.
AU - Harbarth, Stephan
AU - Pittet, Didier
PY - 2005/10
Y1 - 2005/10
N2 - Meticillin was introduced in 1959 to treat infections caused by penicillin-resistant Staphylococcus aureus. In 1961 there were reports from the UK of S aureus isolates that had acquired resistance to meticillin (meticillin-resistant S aureus, MRSA). Similar MRSA isolates were soon found in other European countries, and later from Japan, Australia, and the USA. Today MRSA is a major cause of hospital-acquired infections, and a serious public-health concern. In this forum, we present different perspectives from across the globe to better understand the complexity of the problem, and examine the challenges that individual countries face in trying to control the spread of MRSA.
AB - Meticillin was introduced in 1959 to treat infections caused by penicillin-resistant Staphylococcus aureus. In 1961 there were reports from the UK of S aureus isolates that had acquired resistance to meticillin (meticillin-resistant S aureus, MRSA). Similar MRSA isolates were soon found in other European countries, and later from Japan, Australia, and the USA. Today MRSA is a major cause of hospital-acquired infections, and a serious public-health concern. In this forum, we present different perspectives from across the globe to better understand the complexity of the problem, and examine the challenges that individual countries face in trying to control the spread of MRSA.
UR - https://www.scopus.com/pages/publications/25644461238
U2 - 10.1016/S1473-3099(05)70243-7
DO - 10.1016/S1473-3099(05)70243-7
M3 - Comment/debate
C2 - 16183520
AN - SCOPUS:25644461238
SN - 1473-3099
VL - 5
SP - 653
EP - 663
JO - Lancet Infectious Diseases
JF - Lancet Infectious Diseases
IS - 10
ER -
